Recombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1)

CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1

  • Product No.RPA788Mu02
  • Organism SpeciesMus musculus (Mouse) Same name, Different species.
  • SourceProkaryotic expression
  • HostE.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationSecreted
  • Predicted Molecular Mass27.2kDa
  • Accurate Molecular Mass27kDa(Analysis of differences refer to the manual)
  • Residues & TagsSer34~Val241 with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder
  • Purity> 95%
  • Isoelectric Point6.3
  • Applications Positive Control; Immunogen; SDS-PAGE; WB.
    If bio-activity of the protein is needed, please check active protein.
  • DownloadInstruction Manual
  • UOM 10µg50µg 200µg 1mg 5mg
  • FOB US$ 187  US$ 468  US$ 936  US$ 2808  US$ 7020 
    For more details, please contact local distributors!

SEQUENCE

USAGE

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Chinese Journal of Cancer Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications NCBI: PMC3937742
Leukemia.? High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Pubmed:24732592
Diabetes?Metab Res Rev. PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile Pubmed:24816853
Lancet Haematol Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study PubMed: 26686046
Eur J Cancer.  High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Pubmed:27039170
Journal of Cancer Research and Clinical Oncology Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer article:10.1007
Journal of Hematology & Oncology PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma pubmed:27737703
Lung Cancer. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. pubmed:28212990
Oncotarget Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy. pubmed:27780932
Oncotarget High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients. pubmed:27105512
Oncotarget.  Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma pubmed:27566569
Cancer Immunol Immunother. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. pubmed:28349165
Leukemia Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients leu2016385a
Medicine Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. pubmed:28207525
Allergology International  Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients pubmed:27617656
Medicine Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy PMC5319514
American Journal of Respiratory and Critical Care Medicine Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) Pdf:10.1164
Clinical Lung Cancer Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer Pubmed:29859759
Journal of Rheumatology Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis Pubmed:29419471
Translational Oncology High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma Pubmed:29698935
Immunology Letters Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals Pubmed: 30236481
Journal of Cancer Research and Clinical Oncology Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma Pubmed: 30267213
Annals of Surgical Oncology Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between … Pubmed: 30565045
American Journal of Reproductive Immunology Identification of programmed cell death 1 and its ligand in the testicular tissue of mice Pubmed: 30578744
PLoS One Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated … Pubmed: 30807610
Endocrine Connections Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer Pubmed: 31252406
Scientific Reports Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer Pubmed: 31366979
Critical Reviews in Oncology / Hematology The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer Pubmed: 31675543
PLoS One Clinical implications of APOBEC3A and 3B expression in patients with breast cancer Pubmed: 32176735
Cancers Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study Pubmed: 32085544
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma Pubmed: 32054467
LIVER INTERNATIONAL The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer Pubmed: 32780918
CANCER IMMUNOLOGY IMMUNOTHERAPY Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients Pubmed: 32577816
Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure Pubmed: 32443313
Cancer Immunol Immunother The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte 33688997
Acta Biochim Biophys Sin Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management 34180502
EMBO J Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology 34825707
Mol Pharm A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors 34910492
Mol Hum Reprod Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis Pubmed:35404426
Journal of Nanobiotechnology Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape Pubmed:35705974
Medicina Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A … Pubmed:35208526
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPA788Mu01 Recombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1) Positive Control; Immunogen; SDS-PAGE; WB.
RPA788Mu02 Recombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1) Positive Control; Immunogen; SDS-PAGE; WB.
PAA788Mu01 Polyclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1) WB; IHC; ICC; IP.
PAA788Mu02 Polyclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1) WB; IHC; ICC; IP.
SEA788Mu ELISA Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1) Enzyme-linked immunosorbent assay for Antigen Detection.
AEA788Mu ELISA Kit for Anti-Programmed Cell Death Protein 1 Ligand 1 Antibody (Anti-PDL1) Enzyme-linked immunosorbent assay for Antibody Detection.
LMA788Mu Multiplex Assay Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.